NRSN.US Neurosense Therapeutics Ltd

Healthcare Biotechnology USA Stocks
1.69 USD
Close of Nov 15, 2026
1.10 25.40
Market cap
USD 3.21M
P/E
-
P/B
2.64x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NRSN.US undervalued?

Graham number

The Graham number of Neurosense Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neurosense Therapeutics Ltd fundamental analysis

No fundamental analysis for Neurosense Therapeutics Ltd yet.

Neurosense Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neurosense Therapeutics Ltd

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical tr…

Full company profile